Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Clinical Trial

Official title:
A Multi-center, Prospective Study of the Efficacy and Safety of PD-1 Antibody (Sintilimab) in Combination With Pegaspargase and Erlotinib in the Treatment of Stage IV Extranodal NK/T-cell Lymphoma Unfit for High-intensity Chemotherapy

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Pegaspargase and anlotinib in the treatment of stage IV NK/T-cell lymphoma patients unfit for high-dose chemotherapy.

Clinical Trial Description

Stage IV NK/T-cell lymphoma has a poor prognosis, and autologous hematopoietic stem cell transplantation can improve the prognosis of patients who have achieved remission after chemotherapy. The median survival time for patients who were not suitable for transplantation was about 1 year. Asparaginase is the backbone drug for the treatment of NK/T-cell lymphoma. PD-1 antibody is effective for relapsed/refractory NK/T-cell lymphoma. Our previous study found that anlotinib is active in relapsed/refractory NK/T Cell lymphoma. This study is aimed to investigate the efficacy and safety of Sintilimab, a PD-1 antibody approved in China, in combination with Pegaspargase and anlotinib in the treatment of stage IV NK/T-cell lymphoma patients unfit for high-dose chemotherapy. ;

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, T-Cell
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Clinical Trial Details

NCT number	NCT04004572
Study type	Interventional
Source	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact	Rong Tao, MD., PhD
Phone	+86-21-25077607
Email	hkutao@hotmail.com
Status	Recruiting
Phase	Phase 2
Start date	July 1, 2019
Completion date	December 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05058755` - Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma	N/A
Recruiting	`NCT06314334` - Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma	Phase 2
Completed	`NCT03618238` - Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma	Phase 2
Recruiting	`NCT03623087` - SIMPLE Chemotherapy for NK Lymphoma/Leukaemia	Phase 3
Recruiting	`NCT03107962` - Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma	Phase 2
Recruiting	`NCT03630731` - Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma	Phase 2
Completed	`NCT03936452` - Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma	Phase 2
Recruiting	`NCT04366128` - Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL	N/A
Recruiting	`NCT06376721` - Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma	Phase 1/Phase 2